Literature DB >> 21084199

Depletion of CXCR2 inhibits γ-secretase activity and amyloid-β production in a murine model of Alzheimer's disease.

Pancham Bakshi1, Elaina Margenthaler, Jon Reed, Fiona Crawford, Michael Mullan.   

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder that leads to progressive cognitive decline. Recent studies from our group and others have suggested that certain G-protein coupled receptors (GPCRs) can influence the processing of the amyloid precursor protein (APP). Earlier, we demonstrated that stimulation of a chemokine receptor, CXCR2, results in enhanced γ-secretase activity and in increased amyloid-beta (Aβ) production. Taken together, results obtained from in vitro studies indicate that therapeutic targeting of CXCR2 might aid in lowering Aβ levels in the AD brain. To better understand the precise function and to predict the consequences of CXCR2 depletion in the AD brain, we have crossed CXCR2 knockout mice with mice expressing presenilin (PS1 M146L) and APPsw mutations (PSAPP). Our present study confirms that CXCR2 depletion results in reduction of Aβ with concurrent increases of γ-secretase substrates. At the mechanistic level, the effect of CXCR2 on γ-secretase was not found to occur via their direct interaction. Furthermore, we provide evidence that Aβ promotes endocytosis of CXCR2 via increasing levels of CXCR2 ligands. In conclusion, our current study confirms the regulatory role of CXCR2 in APP processing, and poses it as a potential target for developing novel therapeutics for intervention in AD. Copyright Â
© 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21084199     DOI: 10.1016/j.cyto.2010.10.008

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  20 in total

Review 1.  The immunology of neurodegeneration.

Authors:  Eva Czirr; Tony Wyss-Coray
Journal:  J Clin Invest       Date:  2012-04-02       Impact factor: 14.808

Review 2.  Chemokine receptor CXCR2: physiology regulator and neuroinflammation controller?

Authors:  Mike Veenstra; Richard M Ransohoff
Journal:  J Neuroimmunol       Date:  2012-03-22       Impact factor: 3.478

3.  Targeting CCR3 to Reduce Amyloid-β Production, Tau Hyperphosphorylation, and Synaptic Loss in a Mouse Model of Alzheimer's Disease.

Authors:  Chunyan Zhu; Bing Xu; Xiaohong Sun; Qiwen Zhu; Yi Sui
Journal:  Mol Neurobiol       Date:  2016-11-23       Impact factor: 5.590

Review 4.  Oxidative stress and β-amyloid protein in Alzheimer's disease.

Authors:  Zhiyou Cai; Bin Zhao; Anna Ratka
Journal:  Neuromolecular Med       Date:  2011-09-08       Impact factor: 3.843

Review 5.  The role of G protein-coupled receptors in the pathology of Alzheimer's disease.

Authors:  Amantha Thathiah; Bart De Strooper
Journal:  Nat Rev Neurosci       Date:  2011-02       Impact factor: 34.870

6.  A combination of in vitro techniques for efficient discovery of functional monoclonal antibodies against human CXC chemokine receptor-2 (CXCR2).

Authors:  Ronald S Boshuizen; Catherine Marsden; Johan Turkstra; Christine J Rossant; Jerry Slootstra; Clive Copley; Klaus Schwamborn
Journal:  MAbs       Date:  2014       Impact factor: 5.857

Review 7.  CXCR2: a target for pancreatic cancer treatment?

Authors:  Kathleen M Hertzer; Graham W Donald; O Joe Hines
Journal:  Expert Opin Ther Targets       Date:  2013-02-21       Impact factor: 6.902

8.  Boronic acid-containing aminopyridine- and aminopyrimidinecarboxamide CXCR1/2 antagonists: Optimization of aqueous solubility and oral bioavailability.

Authors:  Aaron D Schuler; Courtney A Engles; Dean Y Maeda; Mark T Quinn; Liliya N Kirpotina; Winston N Wicomb; S Nicholas Mason; Richard L Auten; John A Zebala
Journal:  Bioorg Med Chem Lett       Date:  2015-07-30       Impact factor: 2.823

Review 9.  Modulating neuroinflammation in neurodegeneration-related dementia: can microglial toll-like receptors pull the plug?

Authors:  Rohit Kumar Tiwari; Afrasim Moin; Syed Mohd Danish Rizvi; Syed Monowar Alam Shahid; Preeti Bajpai
Journal:  Metab Brain Dis       Date:  2021-03-11       Impact factor: 3.584

10.  Activation of the nuclear receptor PPARδ is neuroprotective in a transgenic mouse model of Alzheimer's disease through inhibition of inflammation.

Authors:  Tarja Malm; Monica Mariani; Lauren J Donovan; Lee Neilson; Gary E Landreth
Journal:  J Neuroinflammation       Date:  2015-01-16       Impact factor: 9.587

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.